Envíe este artículo por correo electrónico (Inicie sesión)
Enviar un correo electrónico al autor/a (Inicie sesión) Open Journal Systems
Hipertensión arterial pulmonar desde la evaluación del riesgo al tratamiento combinado
Resumen
En este trabajo se señala la importancia de las guías de actuación clínica, así como de los centros de atención integral de la hipertensión arterial pulmonar. Se analiza el tratamiento actual de la hipertensión arterial pulmonar de acuerdo a su severidad, estratificado a través de la evaluación de parámetros múltiples de riesgo y su mortalidad a 1 año. Además, se considera el pronóstico de la enfermedad y el lugar que tiene el tratamiento combinado indicado en forma secuencial o desde un inicio.
Palabras clave
Referencias
Issac M, Dingemanse J, Sidharta PN. Pharmacokinetics of Macitentan in patients with pulmonary arterial hypertension and comparison with healthy subjects. J Clin Pharmacol. 2017;57(8):997-1004.
Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373(26):2522-33.
Galiè N, Barberá JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med. 2015;373(9):834-44.
Farber HW, Miller DP, Poms AD, Badesh DB, Frost AE, Muros-Le Rouzic E, et al. Five-year outcomes of patients enrolled in the REVEAL registry. Chest. 2015;148(4):1043-1054.
Simonneau G, Hoeper MM, McLaughlin V, Rubin L, Galiè N. Future perspectives in pulmonary arterial hypertension. Eur Respir Rev. 2016;25(142):381-89.
Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. Rev Esp Cardiol. 2016;69(2):1-62.
Gaine S, McLaughlin V. Pulmonary arterial hypertension: tailoring treatment to risk in the current era. Eur Respir Rev. 2017;26(146):170095. DOI: 10.1183/16000617.0095-2017.
Raina A, Humbert M. Risk assessment in pulmonary arterial hypertension. Eur Respir Rev. 2016;25(1):390-98.
Galié N, Channick RN, Frantz RP, Grüning E, Chen-Jing Z, Moiseeva O, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J. 2019;53(1):1801889. DOI: 10.1183/13993003.01889-2018.
Boucly A, Weatherald J, Savale L, Jais X, Cottin V, Prevot G, et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J. 2017;50(2):pii: 1700889. DOI: 10.1183/13993003.00889-2017.
Graarup J, Ferrari P, Howard LS. Patient engagement and self-management in pulmonary arterial hypertension. Eur Respir Rev. 2016;25(142):399-407.
Grünig E, Lichtblau M, Ehlken N, Lichtblau M, Nagel C, Fischer C, et al. Safety and efficacy of exercise training in various forms of pulmonary hypertension. Eur Respir J. 2012;40(1):84-92.
Dodson MW, Brown LM, Elliott CG. Pulmonary Arterial Hypertension. Heart Fail Clin. 2018;14(3):255-69.
Weill D, Benden C, Corris PA, Dark JH, Davis RD, Keshavjee S, et al. A consensus document for the selection of lung transplant candidates: 2014- an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2015;34(1):1-15.
Olsson KM, Delcroix M, Ghofrani HA, Tiede H, Huscher D, Speich R, et al. Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation. 2014;129(1):57-65.
Preston IR, Roberts KE, Miller DP, Sen GP, Selej M, Benton WW, et al. Effect of warfarin treatment on survival of patients with pulmonary arterial hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL). Circulation. 2015;132(25):2403-11.
D´Alonso GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Survival en patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991;115(5):343-9.
Sandoval J, Bauerle O, Palomar A, Gómez A, Martínez-Guerra ML, Beltrán M, et al. Survival in primary pulmonary hypertension. Validation of a prognostic equation. Circulation. 1994;89(4):1733-44.
Galié N, Palazzini M, Manes A. Pulmonary arterial hypertension: from the kingdom of the near dead to multiple trial meta-analyses. Eur Heart J. 2010;31(17):2080-86.
Liu HL, Chen XY, Li JR, Su SW, Ding T, Shi CX, et al. Efficacy and safety of pulmonary arterial hypertension-specific therapy in pulmonary arterial hypertension: A meta-analysis of randomized controlled trials. Chest. 2016;150(2):353-66.
Fox BD, Shtraichnan O, Langleben D, Shimony A, Kramer MR. Combination therapy for pulmonary arterial hypertension: A systematic review and meta-analysis. Can J Cardiol. 2016;32(12):1520-30.
Lajoie AC, Lauziére G, Lega JC, Lacasse Y, Martin S, Simard S, et al. Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis. Lancet Respir Med. 2016;4(4):291-305.
Benza RL, Gomberg-Maitland M, Miller DP, Frost A, Frantz RP, Foreman AJ, et al. The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. Chest. 2012;141(2):354-62.
Benza RL, Miller DP, Foreman AJ, Frost AE, Badesch DB, Benton WW, et al. Prognostic implications of serial risk score assessments in patients with pulmonary arterial hypertension: a Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) analysis. J Heart Lung Transplant. 2015;34(3):356-61.
Kylhammar D, Kjellström B, Hjalmarsson C, Jansson K, Nisell M, Söderberg S, et al. A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension. Eur Heart J. 2018;39(47):4175-4181. DOI: 10.1093/eurheartj/ehx257.
Hoeper MM, Kramer T, Pan Z, Eichstaedt CA, Spiesshoefer J, Benjamin N, et al. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir. J. 2017;50(2):pii:1700740. DOI: 10.1183/13993003.00740-2017.
Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010;122(2):156-63.
Waxman AB, Farber HW. Using clinical trial end points to risk stratify patients with pulmonary arterial hypertension. Circulation. 2015;132(22):2152-61.
van de Veerdonk MC, Marcus JT, Westerhof N, de Man FS, Boonstra A, Heymans MW, et al. Signs of right ventricular deterioration in clinically stable patients with pulmonary arterial hypertension. Chest. 2015;147:1063-71.
Burks M, Stickel S, Galiè N. Pulmonary arterial hypertension: Combination therapy in practice. Am J Cardiovasc Drugs. 2018;18(4):249-57.
Vachiéry JL, Galiè N, Barberá JA, Frost AE, Ghofrani HA, Hoeper MM, et al. Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension‒related hospitalization in the AMBITION trial. J Heart Lung Transplant. 2018;22:pii: S1053-2498(18)31742-X. DOI: 10.1016/j.healun.2018.11.006.
Kholdani CA, Fares WH, Trow TK. Macitentan for the treatment of pulmonary arterial hypertension. Vasc Health Risk Manag. 2014;10(1):665-73.
Simonneau G, Channick R, Delcroix M, Galiè N, Ghofrani HA, Jansa P, et al. Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN. Eur Respir J. 2015;46(6):1711-20.
O’Connell C, Amar D, Boucly A, Savale L, Jaïs X, Chaumais MC, et al. Comparative safety and tolerability of prostacyclins in pulmonary hypertension. Drug Saf. 2016; 39(4): 287-94.
Tapson VF, Torres F, Kermeen F, Keogh AM, Allen RP, Frantz RP, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest. 2012;142(6):1383-90.
Tapson VF, Jing ZC, Xu KF, Pan L, Feldman J, Kiely DG, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial. Chest. 2013;144(3):952-58.
Sitbon O, Benza RL, Badesch DB, Barst RJ, Elliott CG, Gressin V, et al. Validation of two predictive models for survival in pulmonary arterial hypertension. Eur Respir J. 2015;46(1):152-64.
Austin ED, Kawut SM, Gladwin MT, Abman SH. Pulmonary hypertension: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases. Ann Am Thorac Soc. 2014;11(3):S178-S85.
Hay BR, Pugh ME, Robbins IM, Hemnes AR. Parenteral prostanoid use at a tertiary referral center: a retrospective cohort study. Chest. 2016;149(3):660-66.
Sitbon O, Jaïs X, Savale L, Cottin V, Bergot E, Macari EA, et al. Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. Eur Respir J. 2014;43(6):1691-97.
Han X, Zhang Y, Dong L, Fang L, Chai Y, Niu M, et al. Treatment of Pulmonary Arterial Hypertension Using Initial Combination Therapy of Bosentan and Iloprost. Respir Care. 2017;62(4):489-96.
Shapiro S, Torres F, Feldman J, Keogh A, Allard M, Blair C, et al. Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a suboptimal therapeutic response (ATHENA-1). Respir Med. 2017;126:84-92.
Enlaces refback
- No hay ningún enlace refback.